{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:46:09Z","timestamp":1791953169326,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.09.017","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:09:17Z","timestamp":1790348957000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world threshold-based eligibility for emerging lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7816-8354","authenticated-orcid":false,"given":"Eva","family":"Steinacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4529-6856","authenticated-orcid":false,"given":"Johannes","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3470-0470","authenticated-orcid":false,"given":"Felix","family":"Wollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9374-3500","authenticated-orcid":false,"given":"Victoria","family":"Radl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2477-3334","authenticated-orcid":false,"given":"Ulrike","family":"Baumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6874-5349","authenticated-orcid":false,"given":"Patrick","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niema","family":"Kazem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayyan","family":"Hemetsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-0935","authenticated-orcid":false,"given":"Alexander","family":"Niessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-2837","authenticated-orcid":false,"given":"Konstantin A.","family":"Krychtiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Koller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-3138","authenticated-orcid":false,"given":"Walter S.","family":"Speidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.09.017_bib1","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.017_bib2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein(a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.017_bib3","unstructured":"Study Details | NCT04023552 | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD | ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT04023552."},{"key":"10.1016\/j.jacl.2026.09.017_bib4","unstructured":"Amgen. A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a). https:\/\/clinicaltrials.gov\/study\/NCT05581303 (2025)."},{"key":"10.1016\/j.jacl.2026.09.017_bib5","unstructured":"Eli Lilly and Company. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a). https:\/\/clinicaltrials.gov\/study\/NCT06292013 (2025)."},{"key":"10.1016\/j.jacl.2026.09.017_bib6","unstructured":"Eli Lilly and Company. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event. https:\/\/clinicaltrials.gov\/study\/NCT07157774 (2025)."},{"key":"10.1016\/j.jacl.2026.09.017_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2026.09.017_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of cardiovascular events and lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O\u2019Donoghue","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2026.09.017_bib9","unstructured":"AmgenA Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a). https:\/\/clinicaltrials.gov\/study\/NCT07136012 (2026)."},{"key":"10.1016\/j.jacl.2026.09.017_bib10","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.017_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.jacl.2026.09.017_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.09.017_bib13","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2025.04.010","article-title":"Global variation in lipoprotein(a) levels among patients with coronary heart disease","volume":"85","author":"Barkas","year":"2025","journal-title":"JACC"},{"key":"10.1016\/j.jacl.2026.09.017_bib14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00508-015-0833-4","article-title":"Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment","volume":"127","author":"Derfler","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jacl.2026.09.017_bib15","unstructured":"Abschlussbericht: Beratungsverfahren \u00dcber Eine \u00c4nderung Der Richtlinie Methoden Vertrags\u00e4rztliche Versorgung (MVV-RL): Dokumentationsvorgaben Zur Indikationsstellung Der Lp(a)-Apherese. https:\/\/www.g-ba.de\/downloads\/40\u2013268-2183\/2013\u201301-17_MVV-RL-DokIndApherese_ZD.pdf (2013)."},{"key":"10.1016\/j.jacl.2026.09.017_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227054","article-title":"Lipoprotein(a) plasma levels are not associated with survival after acute coronary syndromes: an observational cohort study","volume":"15","author":"Roth","year":"2020","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jacl.2026.09.017_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijcard.2015.03.211","article-title":"Variation of lipoprotein(a) plasma levels after premature myocardial infarction","volume":"186","author":"Goliasch","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2026.09.017_bib18","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.017_bib19","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.017_bib20","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.09.017_bib21","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1161\/ATV.0000000000000177","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the american heart association","volume":"44","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2026.09.017_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11883-019-0787-5","article-title":"Current role of lipoprotein apheresis","volume":"21","author":"Thompson","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.jacl.2026.09.017_bib23","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/eurjpc\/zwae007","article-title":"Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity","volume":"31","author":"Leistner","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.09.017_bib24","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the Copenhagen General Population Study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.09.017_bib25","first-page":"e72","article-title":"Inflammatory biomarkers in acute coronary syndromes","volume":"113","author":"Armstrong","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.017_bib26","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.017_bib27","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention","volume":"14","author":"Yoon","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacl.2026.09.017_bib28","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:04:15Z","timestamp":1791950655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":28,"alternative-id":["S1933287426005313"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.017","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world threshold-based eligibility for emerging lipoprotein(a)-targeted therapies in chronic and acute coronary syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}